The stories have been in the U.S. media over and over in the past few years – the cost of a life-saving or maintenance drug suddenly jumps by as much
The company has received approval from the Swedish Medical Products Agency to initiate the first clinical trial with the contrast agent SpagoPix (SN132D) in patients with breast cancer. SpagoPix is
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
Nordic Life Science
The latest clinical trials
Prometic Life Sciences has announced that it has received Swedish Medical Products Agency (MPA) Clinical Trial Application (CTA) approval to commence a clinical trial of its plasminogen therapy in patients
AstraZeneca and its global biologics research and development arm, MedImmune, has announced the results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal
BioInvent announces its plans to expand the therapeutic potential of its lead antibody BI-1206. The current development program will be expanded with an open, single-arm Phase I/IIa clinical study to
The first patient in the CANFOUR clinical trial has received three cycles of treatment with the antibody CAN04 and thereby, the first patient has formally completed the safety evaluation period
Phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the
The company has presented one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. The trial is an
On 10-11 October the 4th annual event Outsourcing in Clinical Trials Nordics will be returning to the capital of Denmark. The 2 day event last September saw over 150 delegates
MedImmune, AstraZeneca’s global biologics R&D arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a
Last Friday, Symphogen presents results from a randomized Phase 2 study with Sym004, a mAb mixture targeting EGFR. Their report ad results has been selected for oral presentation on 11
Medivir announces that the first patient has been enrolled in the company’s phase I/II study of birinapant in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab), which is marketed by MSD.
Moberg Pharma reports positive clinical data for Kerasal Nail/ Emtrix showing that it produces a visible improvement after just one week for nails affected by onychomycosis and/or nail psoriasis. The early
Braeburn Pharmaceuticals and Camurus has announced positive results from a Phase 2 pharmacokinetic study of weekly and monthly buprenorphine (CAM2038) depots in opioid dependent patients with moderate-to-severe non-cancer chronic pain.
The Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment (erlotinib or gefitinib) in previously-untreated patients with locally-advanced or
Cantargia’s clinical trial application to study the antibody CAN04 in patients with cancer has been approved by the regulatory authorities as well as the ethics committees in Denmark and Norway. The review is
New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information. The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders
The latest research news from the Nordic region
This year’s Wallenberg Clinical Scholars conduct clinical research in order to discover markers that can reveal dementia and Parkinson’s disease at an early stage, to develop better treatments for the
Scientist from Uppsala University has discovered a specific host protein that many viruses use for their transport within the cell. With modern DNA sequencing technologies it is relatively easy to
Asthma and high blood pressure drugs influence risk of developing parkinson’s disease. Outwardly, Parkinson’s disease (PD) appears as tremors and stiffness. In the brain, neurons fill with aggregates of α-synuclein
Professor Vessela Kristensen is awarded King Olav V’s Prize for Cancer Research for her research on breast cancer. Kristensen is a Professor at the University of Oslo, and associated to
The Maersk Tower is a research building whose architecture creates a framework for health research. It aims to contribute positively by linking the University of Copenhagen with the surrounding neighbourhoods
The University of Helsinki has recruited Professor Mark Daly of the Broad Institute of MIT and Harvard and Massachusetts General Hospital to lead the Institute for Molecular Medicine Finland (FIMM).